下肢外周动脉疾病发生的危险因素及防治进展
摘要
的下肢动脉粥样斑块形成，血栓形成，进而发生狭窄甚至闭塞的，以间歇性跛行，静息痛为主要临床表现的外周动
脉缺血性疾病。本病多发生于中老年人群，患者常伴有的高血压病，高脂血症，糖尿病等全身基础性疾病及不良习
惯可能与下肢 PAD的发生具有相关性。尽早干预可降低下肢 PAD患者截肢甚至死亡的风险，减轻家庭及社会经济负
担。故本文对导致下肢 PAD的危险因素及防治措施进行综述。
关键词
全文:
PDF参考
[1]Criqui M.H., Matsushita K., Aboyans V., Hess
C.N., Hicks C.W., Kwan T.W., McDermott M.M., Misra
S., Ujueta F.,on behalf of the American Heart Association
Council on Epidemiology and Prevention et al. Lower
Extremity Peripheral Artery Disease: Contemporary
150
Epidemiology, Management Gaps, and Future Directions: A
Scientific Statement from the American Heart Association.
Circulation.2021;144:E171–E191.doi:10.1161/
CIR.0000000000001005.
[2 ]Hi r sch AT, C riqui MH, T reat- Jacob son D,
Regensteiner JG, Creager MA, Olin JW, Krook SH,
Hunninghake DB, Comerota AJ, Walsh ME, et al.Peripheral
arterial disease detection, awareness, and treatment in
primary care.JAMA. 2001;286:1317–1324. doi: 10.1001/
jama.286.11.1317.
[3]Pradhan AD,Aday AW,Beckman JA.The Big MAC
attack on peripheral artery disease.Circulation.2020;141:1211–
1213.doi:10.1161/CIRCULATIONAHA.120.045627.
[4]Song P, Rudan D, Wang M, et al. National and
subnational estimation of the prevalence of peripheral artery
disease (PAD) in China: a systematic review and meta_xfffe_analysis [J]. J Glob Health, 2019, 9(1): 010601 DOI:10.7189/
jogh.09.010601.
[5]任泽平团队，任泽平.中国老龄化研究报告 [J].企
业观察家，2022（04）：76-81.
[6]Polonsky T.S. McDermott M.M.Lower extremity
peripheral artery disease without chronic limb-threatening
ischemia: A review.JAMA.2021;325:2188–2198.
doi:10.1001/jama.2021.2126.
[7]Jelani Q.-U., Petrov M., Martinez S.C., Holmvang
L., Al-Shaibi K., Alasnag M. Peripheral Arterial Disease
in Women: An Overview of Risk Factor Profile, Clinical
Features, and Outcomes.Curr. Atheroscler. Rep.2018;20:40.
doi:10.1007/s11883-018-0742-x.
[8]R.S.M. Davies,1,2 R.K. Vohra,2 A.W. Bradbury1 and
D.J. Adam.The Impact of Hormone Replacement Therapy
on the Pathophysiology of Peripheral Arterial Disease.JAMA.
Eur J Vasc Endovasc Surg.2007 Nov;34(5):569-575.doi:
10.1016/j.ejvs.2007.06.002.
[9]David M Herrington,Timothy D Howard,Gregory A
Hawkins,David M Reboussin,Jianfeng Xu,Siqun L Zheng,K
Bridget Brosnihan,Deborah A Meyers,Eugene R Bleecker.
Estrogen-receptor polymorphisms and effects of estrogen
replacement on high-density lipoprotein cholesterol in
women with coronary disease.JAMA.N Engl J Med.2002 Mar
28;346(13):967-74.doi: 10.1056/NEJMoa012952.
[10]Ray JG, Vermeulen MJ, Schull MJ, Redelmeier
DA.Cardiovascular health after maternal placental syndromes
(CHAMPS): population-based retrospective cohort study.
Lancet.2005;366(9499):1797–1803. doi:10.1016/S0140-
6736(05)67726-4.
[11]Pradhan AD, Shrivastava S, Cook NR, Rifai N,
Creager MA, Ridker PM.Symptomatic Peripheral Arterial
Disease in Women: Nontraditional Biomarkers of Elevated
Risk.Circulation.2008 Feb 12;117(6):823-31.doi:10.1161/
CIRCULATIONAHA.107.719369。
[12]Libby P. Interleukin-1 Beta as a Target for
Atherosclerosis Therapy: Biological Basis of CANTOS and
Beyond.[J]. J Am Coll Cardiol. 2017;70 (18):2278-2289.
doi:10.1016/j.jacc.2017.09.028.
[13 ] P r a d h a n AD,Rif ai N,Ri d k e r PM.S ol u bl e
Intercellular Adhesion Molecule-1,Soluble Vascular
Adhesion Molecule-1, and the Development of Symptomatic
Peripheral Arterial Disease in Men.Circulation. 2002 Aug
13;106(7):820-5.doi:10.1161/01.cir.0000025636.03561.ee.
[14]Rajagopalan,Sriram;Mckay,Ian;Ford,Isobel; Bachoo,
Paul; Greaves, Michael;Brittenden,Julie.(2007).Platelet
activation increases with the severity of peripheral arterial
disease: Implications for clinical management. Journal of
Vascular Surgery,Feb 9, 2007,46(3),485–490.doi:10.1016/
j.jvs.2007.05.039.
[15]Berger, Jeffrey S.; Krantz, Mori J.; Kittelson, John
M.; Hiatt, William R. . (2009).Aspirin for the Prevention
of Cardiovascular Events in Patients With Peripheral
Artery Disease. JAMA, 301(18), 1909–1919.doi:10.1001/
jama.2009.623
[16]A. Burdess; A.E. Michelsen; F. Brosstad; K.A.A.
Fox; D.E. Newby; A.F. Nimmo. (2012).Platelet activation in
patients with peripheral vascular disease: Reproducibility and
comparability of platelet markers. 129(1), 0–55.doi:10.1016/
j.thromres.2011.08.015.
[17]Lessiani, G.; Vazzana, N.; Cuccurullo, C.; Di
Michele, D.; Laurora, G.; Sgrò, G.; Di Ruscio, P.; Simeone,
E.; Di Iorio, P.; Lattanzio, S.; Liani, R.; Ferrante, E.; Davì,
G. . (2010). Inflammation, oxidative stress and platelet
activation in aspirin-treated critical limb ischaemia: Beneficial
effects of iloprost. Thrombosis and Haemostasis, 105(2),
321–328.doi:10.1160/TH10-07-0499.
[18]van Geffen, Johanna P.; Kleinegris, Marie-Claire;
151
现代医学前沿 | 第2卷/第12期
Advances in Mordern Medical
Verdoold, Remco; Baaten, Constance C.F.M.J.; Cosemans,
Judith M.E.M.; Clemetson, Kenneth J.; ten Cate, Hugo;
Roest, Mark; de Laat, Bas; Heemskerk, Johan W.M. . (2015).
Normal Platelet Activation Profile in Patients with Peripheral
Arterial Disease on Aspirin. Thrombosis Research, 135(3),
513–520.doi:10.1016/j.thromres.2014.12.029.
[19]Grenon S.M., Hiramoto J., Smolderen K.G.,
Vittinghoff E., Whooley M.A., Cohen B.E. Association
Between Depression and Peripheral Artery Disease:
Insights from the Heart and Soul Study.J. Am. Heart
Assoc.2012;1:e002667. doi:10.1161/JAHA.112.002667.
[20]Otte C, Marmar CR, Pipkin SS, Moos R, Browner
WS, Whooley MA.Depression and 24-hour urinary cortisol
in medical outpatients with coronary heart disease: the Heart
and Soul Study.Biol Psychiatry. 2004;56:241-247.
[21]O'BRIEN, S. M. (2006).Antidepressant therapy and
C-reactive protein levels. The British Journal of Psychiatry,
188(5), 449–452.doi:10.1192/bjp.bp.105.011015.
[22]Brydon L, Walker C, Wawrzyniak A, Whitehead
D, Okamura H, Yajima J, Tsuda A, Steptoe A.Synergistic
effects of psychological and immune stressors on inflammatory
cytokine and sickness responses in humans.Brain Behav
Immun. 2009;23:217-224.doi:10.1016/j.bbi.2008.09.007.
[23]McDermott MM, Greenland P, Guralnik JM, Liu
K, Criqui MH, Pearce WH, Chan C, Schneider J, Sharma
L, Taylor LM, Arseven A, Quann M, Celic L.Depressive
symptoms and lower extremity functioning in men and
women with peripheral arterial disease.J Gen Intern Med.
2003;18:461-467.
[24]Smolderen KG, Safley DM, House JA, Spertus
JA, Marso SP.Percutaneous transluminal angioplasty:
association between depressive symptoms and diminished
health status benefits.Vasc Med. 2011;16:260-266。doi:
10.1177/1358863X11415568.
[25]Kitta Y.，Obata J.-E.，Nakamura T.，Hirano
M.，Kodama Y.，Fujioka D.，Saito Y. Kawabata K.-I.，
Sano K.，Kobayashi T.，et al. Persistent impairment of
endothelial vasomotor function has a negative impact
on outcome in patients with coronary artery disease。J.
Am. Coll. Cardiol.2009;53：323-330。Doi：10.1016/
j.jacc.2008.08.074.
[26]Rajendran P., Rengarajan T., Thangavel J.,
Nishigaki Y., Sakthisekaran D., Sethi G.,Nishigaki I.The
Vascular Endothelium and Human Diseases.Int.J.Biol.
Sci.2013;9:1057–1069. doi:10.7150/ijbs.7502.
[27 ]Aangi J. Shah,Nichola s Pavlato s,Dine sh K.
Kalra，Preventive Therapies in Peripheral Arterial Disease.
Biomedicines.2023 Dec; 11(12): 3157.doi:10.3390/
biomedicines11123157.
[28]Gaggini M., Gorini F., Vassalle C. Lipids in
Atherosclerosis: Pathophysiology and the Role of Calculated
Lipid Indices in Assessing Cardiovascular Risk in Patients with
Hyperlipidemia.Int. J. Mol. Sci.2022;24:75. doi:10.3390/
ijms24010075.
[29]Takaya N., Yuan C., Chu B., Saam T., Polissar N.L.
Jarvik G.P., Isaac C.,McDonough J,Natiello C.,Small R., et
al.Presence of intraplaque hemorrhage stimulates progression
of carotid atherosclerotic plaques:a high-resolution magnetic
resonance imaging study Circulation.2005;111:2768–2775.
doi:10.1161/CIRCULATIONAHA.104.504167
[30]Ding N., Sang Y., Chen J., Ballew S.H., Kalbaugh
C.A., Salameh M.J., Blaha M.J., Allison M., Heiss G., Selvin
E., et al.Cigarette Smoking, Smoking Cessation, and Long_xfffe_Term Risk of 3 Major Atherosclerotic Diseases.J. Am. Coll.
Cardiol.2019;74:498–507.doi:10.1016/j.jacc.2019.05.049.
[31]Rigotti N.A., Pipe A.L., Benowitz N.L., Arteaga
C., Garza D., Tonstad S.Efficacy and Safety of Varenicline for
Smoking Cessation in Patients with Cardiovascular Disease: a
randomized trialCirculation.2010;121:221–229.doi:10.1161/
CIRCULATIONAHA.109.869008.
[32]Estruch, Ramón; Ros, Emilio; Salas-Salvadó,
Jordi; Covas, Maria-Isabel; Corella, Dolores; Arós,
Fernando; Gómez-Gracia, Enrique; Ruiz-Gutiérrez,
Valentina; Fiol, Miquel; Lapetra, José; Lamuela-Raventos,
Rosa M.; Serra-Majem, Lluís; Pintó, Xavier; Basora,
Josep; Muñoz, Miguel A.; Sorlí, José V.; Martínez, J.
Alfredo; Fitó, Montserrat; Gea, Alfredo; Hernán, Miguel
A.; Martínez-González, Miguel A. . (2018).Primary
Prevention of Cardiovascular Disease with a Mediterranean
Diet Supplemented with Extra-Virgin Olive Oil or Nuts.
New England Journal of Medicine, 2018 Jun 21;378(25):e34.
doi:10.1056/NEJMoa1800389.
[33]Ruiz-Canela M., Estruch R., Corella D., Salas_xfffe_Salvadó J., Martínez-González M.A. Association of
152
Mediterranean Diet with Peripheral Artery Disease: the
PREDIMED randomized trial.JAMA.2014;311:415–417.
doi:10.1001/jama.2013.280618.
[34]Treat-Jacobson D, McDermott MM, Bronas UG,
Campia U, Collins TC, Criqui MH, Gardner AW, Hiatt
WR, Regensteiner JG, Rich K,Optimal exercise programs for
patients with peripheral artery disease: a scientific statement
from the American Heart Association.Circulation.2019;Jan22;
139(4):e10-e33.doi:10.1161/CIR.0000000000000623.
[35]Gerhard-Herman, MD, Gornik, HL, Barrett,
C, Barshes, NR, Corriere, MA, Drachman, DE, Fleisher,
LA, Fowkes, FG, Hamburg, NM, Kinlay, S, Lookstein, R,
Misra, S, Mureebe, L, Olin, JW, Patel, RA, Regensteiner,
JG, Schanzer, A, Shishehbor, MH, Stewart, KJ, TreatJacobson, D, Walsh, ME. 2016 AHA/ACC guideline on
the management of patients with lower extremity peripheral
artery disease: executive summary: a report of the American
College of Cardiology/American Heart Association Task
Force on Clinical Practice Guidelines。Circulation.2017 Mar
21;135(12):e686-e725.doi:10.1161/CIR.0000000000000470.
[36]Esha Arora，G. Arun Maiya，Tom Devasia，Ram
Bhat4，Ganesh Kamath5.Efficacy of comprehensive structured
exercise program on claudication pain and quality of life in
type 2 diabetes mellitus with peripheral arterial disease.Journal
of Diabetes & Metabolic Disorders April (2024) 23:1305–
1313.doi: 10.1007/s40200-024-01426-2.
[37 ]B av ry AA, An de r son RD, Gong Y, et al.
Outcomes Among hypertensive patients with concomitant
peripheral and coronary artery disease: findings from
the INternational VErapamil-SR/ Trandolapril
STudy.Hypertension.2010;55:48–53.doi:10.1161/
HYPERTENSIONAHA.109.142240.
[38]Harm H.H. Feringa; Virginie H. van Waning;
Jeroen J. Bax; Abdou Elhendy; Eric Boersma; Olaf Schouten;
Wael Galal; Radosav V. Vidakovic; Marco J. Tangelder; Don
Poldermans. (2006).Cardioprotective Medication Is Associated
With Improved Survival in Patients With Peripheral Arterial
Disease.47(6), 1182–1187.doi:10.1016/j.jacc.2005.09.074.
[39]Ostergren J, Sleight P, Dagenais G, et al. Impact of
ramipril in patients with evidence of clinical or subclinical
peripheral arterial disease.Eur Heart J.2004;25:17–24.doi:
10.1016/j.ehj.2003.10.033.
[40]Norgren, L.; Hiatt, W.R.; Dormandy, J.A.; Nehler,
M.R.; Harris, K.A.; Fowkes, F.G.R.(2007).Inter-Society
Consensus for the Management of Peripheral Arterial Disease
(TASC II). Journal of Vascular Surgery, 45(1), S5–S67.
doi:10.1016/j.jvs.2006.12.037.
[41]Goldman M.P., Clark C.J., Craven T.E., Davis R.P.,
Williams T.K., Velazquez-Ramirez G., Hurie J.B., Edwards
M.S. Effect of Intensive Glycemic Control on Risk of Lower
Extremity Amputation.J. Am. Coll. Surg.2018;227:596–604.
doi:10.1016/j.jamcollsurg.2018.09.021.
[42]Aday A.W., Lawler P.R., Cook N.R., Ridker
P.M., Mora S., Pradhan A.D. Lipoprotein Particle Profiles,
Standard Lipids, and Peripheral Artery DiseaseIncidence.
Circulation.2018;138:2330–2341.doi:10.1161/
CIRCULATIONAHA.118.035432.
[43]Chapman MJ, Ginsberg HN, Amarenco P, Andreotti
F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen
PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard
BG, Ray KK, Reiner Z, Taskinen M-R, Tokgözoglu L,
Tybjaerg-Hansen A, Watts GF,European Atherosclerosis
Society Consensus Panel. Triglyceride-rich lipoproteins
and high-density lipoprotein cholesterol in patients at high
risk of cardiovascular disease: evidence and guidance for
management.Eur Heart J 2011;32:1345–1361. doi: 10.1093/
eurheartj/ehr112.
[44]Hess C.N., Cannon C.P., Beckman J.A., Goodney
P.P., Patel M.R., Hiatt W.R., Mues K.E., Orroth K.K.,
Shannon E., Bonaca M.P. Effectiveness of Blood Lipid
Management in Patients with Peripheral Artery Disease.
J. Am. Coll. Cardiol.2021;77:3016–3027. doi:10.1016/
j.jacc.2021.04.060.
[45]Skeik, Nedaa; Nowariak, Meagan E; Smith, Jenna
E; Alexander, Jason Q; Manunga, Jesse M; Mirza, Aleem
K; Sullivan, Timothy M.(2020).Lipid-lowering therapies in
peripheral artery disease: A review. Vascular Medicine, 2021
Feb;26(1):71-80. doi:10.1177/1358863X20957091。
[46]Rockman, Caron B.; Maldonado, Thomas S.;
Jacobowitz, Glenn R.; Adelman, Mark A.; Riles, Thomas
S.. (2012).Hormone Replacement Therapy is Associated
With a Decreased Prevalence of Peripheral Arterial Disease in
Postmenopausal Women. Ann Vasc Surg，26(3),411-418.
doi:10.1016/j.avsg. 2011.10.012.
Refbacks
- 当前没有refback。
